Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment

Purpose: Assessments of financial toxicity among patients with metastatic prostate cancer are lacking. Using patient surveys, we sought to identify coping mechanisms and assess characteristics associated with lower financial toxicity. Materials and Methods: Surveys were administered to all patients seen at a single center’s Advanced Prostate Cancer Clinic over a 3-month period. Surveys included the COST-FACIT (COmprehensive Score for Financial Toxicity) and coping mechanism questionnaires. Patients with metastatic disease (lymph nodes, bone, visceral) were included for analysis. Coping mechanisms were compared between patients experiencing low (COST-FACIT >24) vs high (COST-FACIT ≤24) financial toxicity using Fisher’s exact test. Multivariable linear regression was used to evaluate characteristics associated with lower financial toxicity. Results: Overall, 281 patients met inclusion criteria of which 79 reported high financial toxicity. In multivariable analysis, characteristics associated with lower financial toxicity included older age (estimate: 0.36, 95%CI: 0.21-0.52), applying for patient assistance programs (estimate: 4.42, 95%CI: 1.72-7.11), and an annual income of at least $100,000 (estimate: 7.81, 95%CI: 0.97, 14.66). Patients with high financial toxicity were more likely to decrease spending on basic goods (35% vs 2.5%, P < .001) and leisure activities (59% vs 15%, P > .001), as well as use savings (62% vs 17%, P < .001) to pay for their treatment. Conclusions: In this cross-sectional study, patients with metastatic prostate cancer and high financial toxicity were more likely to decrease spending on basic goods and leisure activities and use savings to pay for care. Understanding the impact of financial toxicity on patients’ lives is crucial to inform shared decision-making and interventions designed to mitigate financial toxicity in this population.

[1]  S. Boorjian,et al.  Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients , 2022, The Journal of urology.

[2]  E. Antonarakis,et al.  Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products , 2022, JAMA network open.

[3]  K. Westrich,et al.  Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims , 2022, Journal of managed care & specialty pharmacy.

[4]  N. Keating,et al.  Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. , 2022, Health affairs.

[5]  P. Lefebvre,et al.  Medication adherence among patients with advanced prostate cancer using oral therapies. , 2021, Future oncology.

[6]  R. Shi,et al.  The Effect of Payer Status on Survival of Patients With Prostate Cancer , 2021, Cureus.

[7]  M. Cooperberg,et al.  Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. , 2020, The Journal of urology.

[8]  T. Skolarus,et al.  Adherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer , 2020, Cancer.

[9]  C. Kennedy,et al.  Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study. , 2019, Journal of oncology practice.

[10]  N. Keating,et al.  Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019. , 2019, JAMA.

[11]  Justin P Huynh,et al.  Use of Charity Financial Assistance for Novel Oral Anticancer Agents. , 2018, Journal of oncology practice.

[12]  D. Goldstein,et al.  Trajectories of Injectable Cancer Drug Costs After Launch in the United States. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Gordon,et al.  A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay , 2017, The Patient - Patient-Centered Outcomes Research.

[14]  Y. Shih,et al.  Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Jemal,et al.  Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States , 2017, Cancer.

[16]  L. Zullig,et al.  The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients. , 2017, Journal of managed care & specialty pharmacy.

[17]  Vinay Prasad,et al.  The high price of anticancer drugs: origins, implications, barriers, solutions , 2017, Nature Reviews Clinical Oncology.

[18]  P. Newcomb,et al.  Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Doshi,et al.  Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. , 2015, The Lancet. Haematology.

[20]  E. Bruera,et al.  Financial Distress and Its Associations With Physical and Emotional Symptoms and Quality of Life Among Advanced Cancer Patients. , 2015, The oncologist.

[21]  Thomas J. Smith,et al.  Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Pusztai,et al.  Impact of financial burden of cancer on survivors' quality of life. , 2014, Journal of oncology practice.

[23]  Aaron N. Winn,et al.  Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Abernethy,et al.  Patient-oncologist cost communication, financial distress, and medication adherence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Abernethy,et al.  Full disclosure--out-of-pocket costs as side effects. , 2013, The New England journal of medicine.

[26]  C. Bennett,et al.  Can Patients Afford to Be Adherent to Expensive Oral Cancer Drugs?: Unintended Consequences of Pharmaceutical Development. , 2013, Journal of oncology practice.

[27]  A. Abernethy,et al.  Financial toxicity, Part I: a new name for a growing problem. , 2013, Oncology.

[28]  E. Taylor,et al.  Drug pricing and value in oncology. , 2010, The oncologist.

[29]  W. Shrank,et al.  Drug company-sponsored patient assistance programs: a viable safety net? , 2009, Health affairs.

[30]  L. Casalino,et al.  Patient-physician communication about out-of-pocket costs. , 2003, JAMA.